{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:43:13Z","timestamp":1776087793918,"version":"3.50.1"},"reference-count":33,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Due to the high prevalence of Tourette's disorder among children and adolescents\nand its negative consequences, an appropriate and effective medical treatment with minimal\ncomplications is necessary. Therefore, this study was conducted to compare the effects of Aripiprazole\nand Risperidone on Tourette's disorders in children and adolescents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>The statistical population of this semi-experimental study was children and adolescents aged\nseven to eighteen years old. They were diagnosed with Tourette's disorder based on the DSM-V criteria\nby the clinical interview of a child and adolescent psychiatrist in the child Psychiatry clinic of Ibne-\nSina's Psychiatric Hospital (Mashhad-Iran) in 2018. A total of forty participants were selected by the\nconvenience sampling method, and they were randomly divided into two groups treated with medicines,\nRisperidone or Aripiprazole, for two months. Then, the demographic information questionnaire\nwas completed. The Y-GTSS Scale was completed. The clinical Effect Rating Scale (CGI-Tics Scale)\nwas completed. Calculation of body mass index and medical side effects complications were completed.\nThe evaluation was carried out at the beginning and on the second, fourth, and eighth weeks, and\nthe results were compared. The data were analyzed using SPSS software. 14, descriptive statistics,\nChi-square, and variance analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The two groups were homogeneous in terms of demographic variables and body mass index.\nDespite the positive effect of both medicines, no significant difference was observed among the general\nscores of such disorders, the overall score of severity, Tourette's recovery, and BMI of these two\ngroups at the intervals and the end of treatments. (p &lt;0.05). Due to the low number of complications\nreported, statistical comparisons of the medical side effects were not made.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>According to the results, the two medicines, Aripiprazole and Risperidone, effectively improved\nthe symptoms of Tourette's disorder and its overall severity. However, there were no significant\nstatistical differences between them. Furthermore, in terms of the medical side effects, the statistical\ncomparison between the two medicines was impossible due to the small number of complications.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163820666230609095720","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T05:19:45Z","timestamp":1686547185000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating the Effects and Side Effects of Two Antipsychotic Drugs in\nthe Treatment of Children and Adolescents with Tourette Syndrome: A\nSemi-experimental Research"],"prefix":"10.2174","volume":"20","author":[{"given":"Atefeh","family":"Soltanifar","sequence":"first","affiliation":[{"name":"Psychiatry and Behavioral Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raheleh","family":"Lashkarnevis","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioral Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maliheh","family":"Ziaee","sequence":"additional","affiliation":[{"name":"Community\nMedicine Specialist, Department of Community Medicine, School of Medicine, Social Determinants of Health Research\nCenter, Gonabad University of Medical Sciences, Gonabad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Moharari","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Psychiatry and Behavioral\nSciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roya","family":"Samadi","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioral Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Soltanifar","sequence":"additional","affiliation":[{"name":"Department of Community\nMedicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maedeh","family":"Kamrani","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioral Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Department of Psychiatry,\nFaculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Sadock B.J.","year":"2017","unstructured":"Sadock B.J.; Sadock V.A.; Ruiz P.;  Comprehensive textbook of psychiatry 2017","journal-title":"Comprehensive textbook of psychiatry"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jpsychores.2009.07.010","volume":"67","author":"Robertson M.M.","year":"2009","unstructured":"Robertson M.M.; Eapen V.; Cavanna A.E.; The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: A cross-cultural perspective. J Psychosom Res 2009,67(6),475-483","journal-title":"J Psychosom Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3389\/fpsyt.2016.00011","volume":"7","author":"Sun N.","year":"2016","unstructured":"Sun N.; Tischfield J.A.; King R.A.; Heiman G.A.; Functional evaluations of genes disrupted in patients with Tourette\u2019s disorder. Front Psychiatry 2016,7,11","journal-title":"Front Psychiatry"},{"key":"ref=4","first-page":"275","volume":"27","author":"\u00dcnal D.","year":"2016","unstructured":"\u00dcnal D.; Akdemir D.; Neurobiology of tourette syndrome. Turk Psikiyatr Derg 2016,27(4),275-285","journal-title":"Turk Psikiyatr Derg"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1056\/NEJMcp1007805","volume":"363","author":"Kurlan R.","year":"2010","unstructured":"Kurlan R.; Tourette\u2019s syndrome. N Engl J Med 2010,363(24),2332-2338","journal-title":"N Engl J Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/WCO.0000000000000356","volume":"29","author":"Ganos C.","year":"2016","unstructured":"Ganos C.; Tics and Tourette\u2019s: update on pathophysiology and Tic control. Curr Opin Neurol 2016,29(4),513-518","journal-title":"Curr Opin Neurol"},{"key":"ref=7","first-page":"37","volume":"35","author":"Nagy P.","year":"2020","unstructured":"Nagy P.; Bogn\u00e1r E.; Farkas L.; Clinical characteristics of children with tourette\u2019s syndrome. Psychiatr Hung 2020,35(1),37-45","journal-title":"Psychiatr Hung"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.12688\/f1000research.19542.1","volume":"8","author":"Rose O.","year":"2019","unstructured":"Rose O.; Hartmann A.; Worbe Y.; Scharf J.M.; Black K.J.; Tourette syndrome research highlights from 2018. F1000 Res 2019,8,988","journal-title":"F1000 Res"},{"key":"ref=9","doi-asserted-by":"publisher","DOI":"10.4045\/tidsskr.19.0411","volume":"139","author":"Sur\u00e9n P.","year":"2019","unstructured":"Sur\u00e9n P.; Bakken I.J.; Skurtveit S.; Tourette syndrome in children in Norway. Tidsskr Nor Laegeforen 2019,139(17)","journal-title":"Tidsskr Nor Laegeforen"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fpsyt.2019.00638","volume":"10","author":"Szejko N.","year":"2019","unstructured":"Szejko N.; Jakubczyk A.; Janik P.; Prevalence and clinical correlates of self-harm behaviors in Gilles de la Tourette syndrome. Front Psychiatry 2019,10,638","journal-title":"Front Psychiatry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14737175.2020.1698950","volume":"20","author":"Rizzo R.","year":"2020","unstructured":"Rizzo R.; Gulisano M.; Treatment options for Tic disorders. Expert Rev Neurother 2020,20(1),55-63","journal-title":"Expert Rev Neurother"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/jan.14279","volume":"76","author":"Chen C.W.","year":"2020","unstructured":"Chen C.W.; Wang H.S.; Chang H.J.; Hsueh C.W.; Effectiveness of a modified comprehensive behavioral intervention for Tics for children and adolescents with tourette\u2019s syndrome: A randomized controlled trial. J Adv Nurs 2020,76(3),903-915","journal-title":"J Adv Nurs"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-444-64012-3.00008-3","volume":"165","author":"Deeb W.","year":"2019","unstructured":"Deeb W.; Malaty I.A.; Mathews C.A.; Tourette disorder and other Tic disorders. Handb Clin Neurol 2019,165,123-153","journal-title":"Handb Clin Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1177\/0883073819877335","volume":"35","author":"Gill C.E.","year":"2020","unstructured":"Gill C.E.; Kompoliti K.; Clinical features of tourette syndrome. J Child Neurol 2020,35(2),166-174","journal-title":"J Child Neurol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s00787-019-01386-6","volume":"29","author":"Benaroya-Milshtein N.","year":"2020","unstructured":"Benaroya-Milshtein N.; Shmuel-Baruch S.; Apter A.; Valevski A.; Fenig S.; Steinberg T.; Aggressive symptoms in children with Tic disor-ders. Eur Child Adolesc Psychiatry 2020,29,617-624","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00787-019-01450-1","volume":"29","author":"Openneer T.J.C.","year":"2020","unstructured":"Openneer T.J.C.; T\u00e1rnok Z.; Bognar E.; The Premonitory Urge for Tics Scale in a large sample of children and adolescents: Psychometric properties in a developmental context. An EMTICS study. Eur Child Adolesc Psychiatry 2020,29,1411-1424","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4088\/JCP.18m12717","volume":"80","author":"Mustafa S.","year":"2019","unstructured":"Mustafa S.; Joober R.; Iyer S.; Shah J.; Lepage M.; Malla A.; Early stabilization of weight changes following treatment with olanzapine, risperidone, and aripiprazole: A 12-month naturalistic study of first episode psychosis. J Clin Psychiatry 2019,80(5),1087","journal-title":"J Clin Psychiatry"},{"key":"ref=18","first-page":"296","volume":"7","author":"Padala P.R.","year":"2005","unstructured":"Padala P.R.; Qadri S.F.; Madaan V.; Aripiprazole for the treatment of Tourette\u2019s disorder. Prim Care Companion J Clin Psychiatry 2005,7(6),296-299","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/cap.2007.061","volume":"18","author":"Budman C.","year":"2008","unstructured":"Budman C.; Coffey B.J.; Shechter R.; Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008,18(5),509-515","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=20","first-page":"421","volume":"12","author":"Liu Y.","year":"2010","unstructured":"Liu Y.; Chen Y.; Chen H.; Liu Z.; A control study of aripiprazole and tiapride treatment for Tic disorders in children. Chin J. Contemp Pediatr 2010,12(6),421-424","journal-title":"Contemp Pediatr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hup.798","volume":"21","author":"Davies L.","year":"2006","unstructured":"Davies L.; Stern J.S.; Agrawal N.; Robertson M.M.; A case series of patients with Tourette\u2019s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006,21(7),447-453","journal-title":"Hum Psychopharmacol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1089\/cap.2008.0149","volume":"19","author":"Murphy T.K.","year":"2009","unstructured":"Murphy T.K.; Mutch P.J.; Reid J.M.; Open label aripiprazole in the treatment of youth with Tic disorders. J Child Adolesc Psychopharmacol 2009,19(4),441-447","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.4088\/JCP.v68n0717","volume":"68","author":"Yoo H.K.","year":"2007","unstructured":"Yoo H.K.; Choi S.H.; Park S.; Wang H.R.; Jin-Pyo J-P.; Kim C.Y.; An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with Tic disorders. J Clin Psychiatry 2007,68(7),1089-1094","journal-title":"J Clin Psychiatry"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/cap.2009.0035","volume":"19","author":"Lyon G.J.","year":"2009","unstructured":"Lyon G.J.; Samar S.; Jummani R.; Aripiprazole in children and adolescents with Tourette\u2019s disorder: An open-label safety and tolerability study. J Child Adolesc Psychopharmacol 2009,19(6),623-633","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10578-013-0427-1","volume":"45","author":"Ghanizadeh A.","year":"2014","unstructured":"Ghanizadeh A.; Haghighi A.; Aripiprazole versus risperidone for treating children and adolescents with Tic disorder: A randomized double blind clinical trial. Child Psychiatry Hum Dev 2014,45(5),596-603","journal-title":"Child Psychiatry Hum Dev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00787-010-0154-0","volume":"20","author":"Yoo H.K.","year":"2011","unstructured":"Yoo H.K.; Lee J.S.; Paik K.W.; Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric Tic disorders. Eur Child Adolesc Psychiatry 2011,20(3),127-135","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/PHMT.S87121","volume":"7","author":"Cox J.","year":"2016","unstructured":"Cox J.; Seri S.; Cavanna A.; Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic Tic disorders. Pediatric Health Med Ther 2016,7,57-64","journal-title":"Pediatric Health Med Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cct.2013.08.012","volume":"36","author":"Jeon S.","year":"2013","unstructured":"Jeon S.; Walkup J.T.; Woods D.W.; Detecting a clinically meaningful change in Tic severity in Tourette syndrome: A comparison of three methods. Contemp Clin Trials 2013,36(2),414-420","journal-title":"Contemp Clin Trials"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/2231-4040.177203","volume":"7","author":"Hasanpour-Dehkordi A.","year":"2016","unstructured":"Hasanpour-Dehkordi A.; Safavi P.; AmirAhmadi M. Comparison of risperidone and aripiprazole in the treatment of preschool children with disruptive behavior disorder and attention deficit-hyperactivity disorder: A randomized clinical trial. J Adv Pharm Technol Res 2016,7(2),43-47","journal-title":"J Adv Pharm Technol Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e15816","DOI":"10.1097\/MD.0000000000015816","volume":"98","author":"Yang C.","year":"2019","unstructured":"Yang C.; Yi Q.; Zhang L.; Cui H.; Mao J.; Safety of aripiprazole for Tics in children and adolescents. Medicine 2019,98(22),e15816","journal-title":"Medicine"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1024\/1422-4917\/a000049","volume":"38","author":"Fr\u00f6lich J.","year":"2010","unstructured":"Fr\u00f6lich J.; Starck M.; Banaschewski T.; Lehmkuhl G.; A drug treatment alternative for Tourette\u2019s syndrome in children and adolescents. Z Kinder Jugendpsychiatr Psychother 2010,38,291-298","journal-title":"Z Kinder Jugendpsychiatr Psychother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/cap.2009.0125","volume":"20","author":"Cui Y.","year":"2010","unstructured":"Cui Y.; Zheng Y.; Yang Y.; Liu J.; Li J.; Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette\u2019s disorder: A pilot study in China. J Child Adolesc Psychopharmacol 2010,20(4),291-298","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1017\/S1461145705005365","volume":"8","author":"Murphy T.K.","year":"2005","unstructured":"Murphy T.K.; Bengtson M.A.; Soto O.; Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005,8(3),489-490","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163820666230609095720","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/217825\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570163820666230609095720","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T11:48:46Z","timestamp":1699616926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/217825\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163820666230609095720","relation":{},"ISSN":["1570-1638"],"issn-type":[{"value":"1570-1638","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e090623217825"}}